Relmada Therapeutics, Inc. (RLMD): Price and Financial Metrics
RLMD Price/Volume Stats
| Current price | $2.79 | 52-week high | $38.68 |
| Prev. close | $2.85 | 52-week low | $1.81 |
| Day low | $2.74 | Volume | 12,020 |
| Day high | $2.90 | Avg. volume | 231,827 |
| 50-day MA | $2.78 | Dividend yield | N/A |
| 200-day MA | $9.23 | Market Cap | 83.98M |
RLMD Stock Price Chart Interactive Chart >
Relmada Therapeutics, Inc. (RLMD) Company Bio
Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.
Latest RLMD News From Around the Web
Below are the latest news stories about RELMADA THERAPEUTICS INC that investors may wish to consider to help them evaluate RLMD as an investment opportunity.
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare ConferenceRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Thursday, June 8, 2023, at 3:00pm ET in New York, NY. Please find additional details about the |
Relmada Therapeutics Insider Ups Holding By 62% During Year \From what we can see, insiders were net buyers in Relmada Therapeutics, Inc.'s ( NASDAQ:RLMD ) during the past 12... |
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual MeetingRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in-person in two late-breaking poster presentations at the American Society of Clinical Psychopharmacology 2023 Annual Meeting. The conference is being held Tuesday, May 30 – Friday, June 2, 2023, in Miami, FL. |
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023. The Company will host a conference call today, Thursday, May 11, at 4:30 PM Eastern Time/1:30 PM Pacific Time. |
Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 11th, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023. |
RLMD Price Returns
| 1-mo | -13.35% |
| 3-mo | -15.20% |
| 6-mo | 28.57% |
| 1-year | -84.48% |
| 3-year | -94.15% |
| 5-year | -52.22% |
| YTD | -20.06% |
| 2022 | -84.51% |
| 2021 | -29.75% |
| 2020 | -17.77% |
| 2019 | 747.83% |
| 2018 | 53.33% |
Loading social stream, please wait...